HBsAg ayw, 31kDa
Description
Product Specs
MGQNLSTSNP LGFFPDHQLD PAFRANTANP DWDFNPNKDT WPDANKVGAG AFGLGFTPPH
GGLLGWSPQA QGILQTLPTN PPPASTNRQS GRQPTPLSPP LRNTHPQAMQ WNSTTFHQTL
QDPRVRGLYF PAGGSSSGTV NPVPTTVSPI SSIFSRIGDP TRILTIPQSL DSWWTSLNFL
GGTTVCLGQN SQSPTSNHSP TSCPPTCGYR WMCLMLPVCP LIPGSSTTTG PCRTCTTPAQ
GTMYPSCCCT KPSDGNCTCP IPSSWAFGKF LWEWASHHHH HH
Q&A
Here’s a structured FAQ collection addressing research-oriented inquiries about HBsAg ayw (31kDa), synthesized from peer-reviewed studies and technical specifications:
What structural features distinguish HBsAg ayw (31kDa) from other HBV subtypes?
HBsAg ayw is characterized by:
-
A 31kDa molecular weight and full-length S domain (226 amino acids) with an N-terminal 6xHis tag for purification .
-
Unique subtype-specific residues: lysine (K) at position 122 (d/y determinant) and arginine (R) at position 160 (w/r determinant) .
-
A conserved major hydrophilic region (MHR, aa 99–169) critical for antibody recognition, which is prone to immune-escape mutations .
Methodological note: Subtype differentiation requires sequencing codons 122 and 160 (e.g., via PCR-cloning followed by Sanger sequencing) .
How is recombinant HBsAg ayw produced and validated for research?
-
Production: Expressed in E. coli with a 6xHis tag, purified via affinity chromatography .
-
Validation:
Key parameter: Storage at -18°C in 50% glycerol to prevent aggregation .
How do N-linked glycosylation patterns affect HBsAg ayw antigenicity?
HBsAg ayw contains a conserved glycosylation site at N146, but immune-escape mutations (e.g., T115N, T123N) can introduce additional glycosylation sites:
| Mutation | Glycosylation Site | Antigenicity Reduction | Citation |
|---|---|---|---|
| T115N | N115-X-T117 | 62% (vs. wild-type) | |
| T123N | N123-X-T125 | 78% | |
| S113N+T131N+M133T | Multi-site | 89% |
Experimental design:
-
Treat transfected Huh7 cells with tunicamycin (1 µg/mL) to inhibit glycosylation and compare antigenicity via ELISA .
-
Use N-Glycosite algorithm (LANL HIV Database) to predict glycosylation motifs .
What molecular techniques resolve discrepancies in HBsAg antigenicity studies?
Conflicting data often arise from:
-
Mutation clusters: Double mutants (e.g., K120P/D123T) restore antigenicity by altering conformational epitopes .
-
Assay variability: Commercial ELISAs differ in antibody affinity for mutated epitopes .
Resolution workflow:
-
Site-directed mutagenesis to isolate single/double mutants .
-
Parallel testing with ≥3 ELISA kits (e.g., Abbott ARCHITECT, Roche Elecsys) .
-
Structural modeling using CLC Sequence Viewer to map mutated residues on 3D HBsAg models .
How does HBsAg ayw interact with hepatocyte receptors?
The pre-S1 domain binds an 80kDa hepatocyte membrane protein (p80) via:
-
Key residues: Asp123 in pre-S1 forms hydrogen bonds with p80 .
-
Subtype specificity: Binding occurs in both ayw and adr subtypes but with 22% lower affinity for ayw .
Method:
-
Competitive inhibition: Preincubate hepatocytes with synthetic pre-S1 peptides (aa 21–47) to block HBV entry .
Why do some studies report intact secretion of hyper-glycosylated HBsAg ayw despite reduced antigenicity?
-
Hypothesis: Additional glycosylation shields epitopes but doesn’t disrupt secretion machinery (e.g., COPII vesicles) .
-
Supporting data:
Resolution: Use PNGase F treatment to deglycosylate HBsAg pre-ELISA, confirming epitope masking .
Product Science Overview
Hepatitis B virus (HBV) is a small, enveloped virus belonging to the Hepadnaviridae family. It causes hepatitis B, a disease characterized by liver inflammation, damage, and an increased risk of hepatocellular carcinoma. The HBV genome consists of partially double-stranded circular DNA, which encodes several viral proteins, including the surface proteins (pre-S1, pre-S2, and HBsAg), the pre-core and core proteins (HBeAg and HBcAg), DNA polymerase, and the X protein .
The surface antigen of HBV, known as HBsAg, is a key marker for screening and monitoring HBV infection. HBsAg is a spherical envelope protein that surrounds the nucleocapsid (core antigen, HBcAg). It plays a crucial role in the virus’s ability to infect liver cells and is the primary target for the immune response against HBV .
HBV exhibits strain heterogeneity, leading to distinct subtypes characterized by antigenic determinants on the surface antigen (HBsAg) and their corresponding antibodies. All HBsAg specimens possess a common group determinant, known as “a.” However, there are two sets of subdeterminants, namely “d” or “y” and “w” or “r,” which are mutually exclusive or allelic. These subdeterminants are used to identify different subtypes. Based on the antigenic variations, HBsAg can be classified into at least four major groups: adw, ayw, adr, and ayr .
Recombinant HBsAg ayw is a genetically engineered version of the surface antigen. It is produced using recombinant DNA technology, where the gene encoding HBsAg is inserted into a host organism, such as yeast (Saccharomyces cerevisiae) or bacteria (Escherichia coli). The host organism then expresses the HBsAg protein, which can be purified and used for various applications, including vaccine production .
One specific recombinant HBsAg ayw variant involves a mutation at position 145, where the glycine residue is replaced with arginine (G-145-R). This mutation has important implications for the antigen’s behavior and immunogenicity. The recombinant HBV Surface Antigen (subtype ayw, mutation G-145-R) is widely used in the development and production of vaccines against hepatitis B .
Recombinant HBsAg ayw is crucial for the development of hepatitis B vaccines. Vaccination is one of the most effective strategies for preventing hepatitis B infection and its associated complications. The recombinant antigen is used to stimulate the immune system to produce antibodies against HBV, providing immunity to the virus. Additionally, recombinant HBsAg is used in diagnostic assays to detect HBV infection and monitor the effectiveness of vaccination .
